P-236 New polyclonal antibody therapeutic to treat esophageal adenocarcinoma and Barrett’s esophagus by targeting EPHB4

Abstract

We have previously shown that human ephrin receptor B 4 (EPHB4) is overexpressed in human mucosal biopsies from esophageal adenocarcinoma (AEC) and its precursor Barrett’s esophagus (BE). With the current standard of care, overall survival at 5 years in patients with AEC is < 20%. Endoscopic ablation of BE in patients presenting with high-grade dysplasia has been shown to reduce the rate of progression to AEC, but ablation is costly and invasive. In non-dysplastic BE patients (the majority) treatment options are limited, mostly consist of reflux control with proton pump inhibitors to minimize further damage to the affected tissue, and their effectiveness and ability to prevent progression to AEC is debatable.